论文信息 - 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma - 字舞流文

2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma

A. Oza | J. Ledermann | R. Coleman | C. Aghajanian | A. Leary | N. Colombo | G. Scambia | S. Goble | A. Clamp | P. Fong | A. Oaknin | J. Weberpals | D. O’Malley | D. Lorusso | A. Dean | L. Maloney | J. Goh | M. A. Gancedo | Robert W. Holloway | Robert W Holloway